Cases & Deals

  • Home
  • Practices
  • Idenix challenges Gilead's patent rights to methods of treating HCV with Sovaldi® (sofosbuvir)

Share

Idenix challenges Gilead's patent rights to methods of treating HCV with Sovaldi® (sofosbuvir)

February 2016

Client(s) Idenix Pharmaceuticals LLC

Jones Day represents Idenix Pharmaceuticals LLC (a subsidiary of Merck & Co., Inc.) in a patent interference against Gilead. Subject matter is methods for treating a host infected with hepatitis C virus by administering a nucleoside analog or prodrug.

Storer v. Clark, Interference 105,981 (USPTO Patent Trial and Appeal Board)

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.